Fig. 1 | npj Vaccines

Fig. 1

From: FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

Fig. 1

a FIV and HIV utilize analogous modes of receptor-mediated cell entry. HIV binds to CD4+ target cells through a high-affinity interaction with the CD4 receptor, inducing a conformational change in the envelope glycoprotein gp120 (SU) that exposes the CXCR4 co-receptor binding site and subsequent fusion with the cell membrane. FIV utilizes a primary receptor CD134, and similar to HIV, binding of FIV Env to the CD134 receptor alters the conformation of envelope glycoprotein gp95 surface (SU) component to facilitate CXCR4 co-receptor binding, and viral entry. b Anti-CD134 antibodies prevent FIV infection in the presence of viral glycoproteins. Binding of FIV SU to CD134 induces a conformational change in the receptor and exposes a cryptic epitope that results in anti-CD134 generation. Anti-CD134 antibody binding to CD134 induces a second conformational change in the CD134 receptor that displaces SU from the cell surface, resulting in inhibition of infection.31

Back to article page